Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Submissions Drop To Start FY2021

Perhaps Forced Down By COVID-19

Executive Summary

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.

You may also be interested in...



ANDA Approval Decline Continues, But Why?

US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.

Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals

ANDA approval rates have remained steady, while submission rates dropped compared to prior years.

FDA Guides On Bioequivalence Studies And COVID-19

Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel